Muutke küpsiste eelistusi

COVID-ology: A Field Guide [Pehme köide]

  • Formaat: Paperback / softback, 224 pages, kõrgus x laius: 229x152 mm, kaal: 500 g, 7 Tables, black and white; 5 Line drawings, color; 11 Line drawings, black and white; 8 Halftones, black and white; 5 Illustrations, color; 19 Illustrations, black and white
  • Ilmumisaeg: 16-Dec-2022
  • Kirjastus: CRC Press
  • ISBN-10: 1032316039
  • ISBN-13: 9781032316031
Teised raamatud teemal:
COVID-ology: A Field GuideSuurem pilt
  • Formaat: Paperback / softback, 224 pages, kõrgus x laius: 229x152 mm, kaal: 500 g, 7 Tables, black and white; 5 Line drawings, color; 11 Line drawings, black and white; 8 Halftones, black and white; 5 Illustrations, color; 19 Illustrations, black and white
  • Ilmumisaeg: 16-Dec-2022
  • Kirjastus: CRC Press
  • ISBN-10: 1032316039
  • ISBN-13: 9781032316031
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9781032316031.html
Märksõnad:
The COVID-19 outbreak and response has been characterized by institutional missteps, media misinformation, and economic and social upheavals. This book is intended to de-mystify and inform in a succinct and straightforward text. The lessons shared are applicable to other infectious diseases and future inevitable pandemics. Readers will learn about the origins of COVID-19, the disease it causes, tests and how they work, therapeutics and prophylactic measures such as vaccines. This text prepares readers to be better able to respond to future emerging infectious diseases and pandemics.

Key Features











Positively influences career choices within public health





Applies basic science to problems raised by the COVID-19 pandemic such as vaccine development and herd immunity





Prepares readers with context and tactics for understanding future infectious disease outbreaks





Successfully used in college senior health sciences seminars





Engaging and balanced treatment of the politicization of public health issues, especially COVID-19

Related Titles

Goswami, S. & C. Day, eds. COVID-19 and SARS-CoV-2: The Science and Clinical Application of Conventional and Complimentary Treatments (ISBN 9781032011950).

Koley, T. K. & M. Dhole. The COVID-19 Pandemic: The Deadly Coronavirus Outbreak (ISBN 9780367558895).

Ryan, J. M., ed. COVID-19 Two volume set (ISBN 9780367740610).
Acknowledgments xv
Author xvii
Acronyms xix
COVID-19 Timeline xxiii
Introduction: Foray into the Field
1(1)
COVID-19 Update: May 9, 2022
1(3)
A Bewildering Landscape
2(1)
An Emerging Infectious Diseases Field Guide
2(1)
Using This Field Guide
3(1)
The Many Paths of Exploration
4(1)
Venturing into COVID-19---and EIDs
4(1)
Notes
5(2)
Chapter 1 The SARS-CoV-2 Virus
7(22)
Field Expedition: NASA's Ten-Word Definition of Life
7(2)
Lesson Learned: NASA's Ten-Word Definition of Life
9(1)
Concepts Covered in This
Chapter
10(17)
Nucleic Acids Are the Self-Sustaining Chemical System of Life
10(3)
The Virus as Industrial Insurrectionist
13(2)
Virus Classification Systems
15(1)
The SARS-CoV-2 Genome
16(1)
SARS-CoV-2 Is a Single-Stranded Positive Sense RNA Virus
17(1)
Protein Translation Starts with ORF1a Making NSP1-NSP11
17(2)
Protein Translation Continues with ORF1b Making NSP12-NSP16
19(1)
Immune System Evasion and Accessory Proteins
20(1)
SARS-CoV-2 Life Cycle
20(1)
SARS-CoV-2 Cell Entry, Cytoplasmic Replication, and Exit
21(1)
Interrupting the Virus Life Cycle
21(2)
Virus Mutability
23(1)
How Mutations Occur
23(1)
Mutation Terminology
24(1)
SARS-CoV-2 Variants
25(1)
More Variants: Not If, but When
26(1)
Looking Back, Looking Ahead
26(1)
Future Outings
27(1)
Student Research Questions
27(1)
Notes
28(1)
Chapter 2 The Origins of SARS-CoV-2
29(14)
Field Expedition: The Bat Woman
29(1)
Lesson Learned: The Bat Woman
30(1)
Concepts Covered in This
Chapter
31(8)
SARS-CoV-2: An Emerging Infectious Disease
31(2)
Zoonotic Spillover Theory
33(1)
Bats as Animal Reservoirs for Lethal Zoonotic Pathogens
33(2)
Laboratory Leak Theory
35(2)
Official Reviews of Laboratory Leak and Zoonotic Spillover Theories
37(1)
Looking Back, Looking Ahead
38(1)
Future Outings
39(2)
Student Research Questions
39(2)
Notes
41(2)
Chapter 3 COVID-19 Disease Manifestations
43(12)
Field Expedition: The Three Phases of Syphilis
43(2)
Lessons Learned: The Three Phases of Syphilis
45(1)
Concepts Covered in This
Chapter
45(8)
COVID-19 Is a New Disease Entity
46(1)
Symptoms
46(1)
COVID-19 Symptoms
46(2)
Clinical Stages
48(1)
COVID-19 Clinical Stages
48(1)
Host Factors
49(1)
COVID-19 Host Factors
49(1)
Comorbid Conditions
49(1)
COVID-19 Comorbid Conditions
50(1)
Pathophysiology
50(1)
COVID-19 Pathophysiology
50(1)
ACE2 Receptors, Fluid Balance, and Inflammation
50(1)
Alveolar Epithelial Cells
51(1)
Acute Respiratory Distress Syndrome
51(1)
PASC andMIS-C
52(1)
Looking Back, Looking Ahead
52(1)
Future Outings
53(2)
Student Research Questions
53(2)
Chapter 4 Testing
55(20)
Field Expedition: Michael Mina's Mission
56(1)
Lesson Learned: Michael Mina's Mission
57(1)
Concepts Covered in This
Chapter
57(15)
Types of Clinical Tests
57(1)
Performance Characteristics of Clinical Tests
58(1)
"Gold Standard" or Reference Standard Test
59(1)
Positive and Negative Predictive Values
60(1)
Clinical Test Results and Disease Probability
60(1)
Bayes's Theorem of Pre-Test Probability
61(1)
Making the Correct Diagnosis of a Disease
61(1)
Using Clinical Tests in Making Diagnoses
62(1)
Making the Correct Diagnosis of COVID-19
63(1)
SARS-CoV-2 Clinical Tests
64(1)
Serologic Antibody Tests
64(1)
PCR Tests
65(3)
RDTs
68(2)
Using Clinical Tests in Making COVID-19 Diagnoses
70(1)
Looking Back, Looking Ahead
71(1)
Future Outings
72(1)
Student Research Questions
72(1)
Notes
72(3)
Chapter 5 Therapeutics
75(28)
Field Expedition: The Strange Case of Ivermectin
76(3)
Lesson Learned: The Strange Case of Ivermectin
79(1)
Concepts Covered in This
Chapter
80(19)
Non-Pharmaceutical Interventions (NPIs)
80(1)
NPIs in Another Age: The 1918 Influenza Pandemic
81(3)
The Path to Scientifically Sound Therapeutics
84(1)
Scientific Method
84(1)
Randomized Clinical Trials (RCTs)
85(1)
Peer-Reviewed Journals
85(1)
Consolidated Statement of Reporting Trials (CONSORT)
86(1)
Pharmacologic Principles
86(2)
Designing Therapeutic Agents: Viral Life Cycle and Pathophysiology
88(1)
Viral Life Cycle
88(2)
Viral-Induced Pathophysiology
90(1)
Three Challenges in Developing Antiviral Medications
91(2)
National Institutes of Health COVID-19 Treatment Guidelines
93(1)
NIH COVID-19 Treatment Recommendations
94(1)
Paxlovid™ (Ritonavir-Boosted Nirmatrelvir)
94(2)
Remdesivir
96(1)
Bebtelovimab
97(1)
Molnupiravir
97(1)
NPIs and Therapeutics as Dual Measures
98(1)
Looking Back, Looking Ahead
98(1)
Future Outings
99(1)
Student Research Questions
99(1)
Notes
100(3)
Chapter 6 Regulatory Agencies
103(18)
Field Expedition: The Booster Announcement
103(3)
Lesson Learned: The Booster Announcement
106(1)
Concepts Covered in This
Chapter
107(10)
The United States: A Constitutional Federal Republic
107(1)
Regulatory Agencies as the "Fourth Branch" of Government
108(1)
Two Key Regulatory Agencies: The CDC and FDA
109(1)
Legal Framework
110(1)
Centers for Disease Control and Prevention (CDC)
111(1)
Food and Drug Administration (FDA)
112(2)
FDA Approval Process
114(1)
Emergency Use Authorization
115(1)
The Pandemic as Civics Lesson
116(1)
Looking Back, Looking Ahead
117(1)
Future Outings
117(1)
Student Research Questions
118(1)
Notes
118(3)
Chapter 7 Vaccines
121(24)
Field Expedition: Jeryl Lynn's Mumps
121(2)
Lesson Learned: Jeryl Lynn's Mumps
123(1)
Concepts Covered in This
Chapter
124(17)
Dr. Jenner's Variolation Experiments
124(1)
A Vaccination Triumph: The Eradication of Smallpox
125(1)
The Smallpox Vaccine
126(1)
How Vaccines Work
126(1)
Vaccines Usurp the Immune System
127(1)
Immune System Response to Infection
128(1)
Interactions among Immunologic Cells of the Adaptive Immune System
129(1)
Vaccine Formulation
129(1)
Types of Vaccines
130(1)
Vaccine Clinical Trials
131(1)
Clinical Trials and Scientific Truth
131(1)
Clinical Trial Phases
132(1)
SARS-CoV-2 Vaccines
133(2)
Four Reasons for Rapid Development of mRNA-Based Vaccines
135(1)
Earlier Work with mRNA Technology
135(1)
Lessons Learned from SARS and MERS
135(1)
Release of the SARS-CoV-2 Genomic Sequence
136(1)
Operation Warp Speed
136(1)
Vaccine Confusion: Too Much of a Good Thing
136(1)
Vaccine Hesitancy and Resistance
137(1)
Existing Background of Distrust
138(1)
State Response to Vaccine Hesitancy
139(1)
Looking Back, Looking Ahead
140(1)
Future Outings
141(1)
Student Research Questions
141(1)
Notes
142(3)
Chapter 8 Herd Immunity
145(16)
Field Expedition: Sweden's Risky Experiment
145(2)
Lesson Learned: Sweden's Risky Experiment
147(1)
Concepts Covered in This
Chapter
147(10)
What Is Herd Immunity?
148(1)
Herd Immunity Threshold
148(2)
Herd Immunity during COVID-19
150(1)
Natural Immunity
151(1)
Conferred Immunity
151(1)
Herd Immunity during the Pre-Vaccination Phase
151(1)
Great Barrington Declaration vs. John Snow Memorandum
152(2)
Herd Immunity during the Post-Vaccination Period
154(1)
Herd Immunity Threshold in the Post-Vaccination Period
155(1)
Herd Immunity vs. "A Path to Normality"
156(1)
Looking Back, Looking Ahead
156(1)
Future Outings
157(2)
Student Research Questions
158(1)
Notes
159(2)
Chapter 9 Global Concerns
161(16)
Field Expedition: The World Health Organization Strategy
161(2)
Lesson Learned: The WHO Strategy
163(1)
Concepts Covered in This
Chapter
164(8)
What Vaccinating the World Means
164(1)
SARS-CoV-2 Vaccination Begins
165(2)
Twenty-First Century Problems
167(1)
From Eradicating Smallpox to Eliminating Other Infectious Diseases
168(1)
Public-Private Partnerships: Gavi, CEPI, and COVAX
168(1)
Bill and Melinda Gates Foundation
169(1)
Gavi, the Vaccine Alliance
170(1)
Coalition for Epidemic Preparedness Innovation (CEPI)
170(1)
COVID-19 Vaccines Global Access Facility (COVAX)
170(1)
Looking Back, Looking Ahead
171(1)
Future Outings
172(1)
Student Research Questions
172(1)
Notes
173(4)
Chapter 10 Covidiocy
177(22)
Field Expedition: Vector in Chief
177(2)
Lesson Learned: Vector in Chief
179(1)
Concepts Covered in This
Chapter
180(7)
The COVID-19 Infodemic
180(1)
The Overabundance of Information
181(1)
The Misuse of Information
181(1)
The Harmful Consequences of Misinformation
181(1)
Covidiocy
182(1)
Irrational Behaviors and Beliefs Observed during the Pandemic
183(1)
Underlying Causes and Driving Forces for Irrational Behavior
184(1)
Logical Fallacies
185(1)
Bias
185(1)
Cultural Values
186(1)
Looking Back, Looking Ahead
186(1)
Future Outings
187(1)
Student Research Questions
187(1)
Notes
188(3)
Conclusion: Our Pandemic Future
191(1)
The White House Correspondents' Dinner
191(1)
Personal Risk Assessment
192(1)
New Threats on the Horizon
193(2)
New Variants and COVID-24
194(1)
H5N1 Avian Flu
194(1)
Monkeypox
194(1)
What's Old Is New Again: Re-Emerging Diseases
195(1)
Our Pandemic Future
196(1)
Notes
197(2)
Glossary 199(16)
Index 215
Dr. Michael T. Myers, Jr., MD, MBA is an Adjunct Lecturer at Stonehill College in Easton, Massachusetts, where he teaches about COVID-19 and is scientific advisor to its COVID-19 Testing Program. With 33 years of experience in health care, Dr. Myers is Chief Medical Officer of Compass Medical, among the largest primary care groups in Massachusetts. Dr. Myers received his MD from Harvard Medical School, MBA from Northeastern University, and BA from Johns Hopkins University.